Butal/Apap/Caff
Brand Names: Butal/Apap/Caff Generic
Methodology & AI Transparency ⓘ
Butal/Apap/Caff Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within prescription barbiturate care, Butal/Apap/Caff (72189-441; manufactured/labeled by Direct_Rx) offers oral-route delivery via 50 mg/1 / 40 mg/1 Tablet with structured clinical follow-up.
- 2 Real-world patient consensus: Tracked across 22 patient dosage logs with a 80% satisfaction benchmark (RxCUI RXN-72189441-3137).
- 3 Typical cash cost range: Public pharmacy ledger: $134.86 low cash benchmark vs. $330.41 chain retail average ($3.1200/unit CMS NADAC).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Butal/Apap/Caff: nausea (7.6%), headache (7.7%), dizziness (6.5%).
Ask our AI Specialists anything about Butal/Apap/Caff
Butal/Apap/Caff Mechanism, CYP450 Pathways & DailyMed Monograph
Within prescription barbiturate care, Butal/Apap/Caff (72189-441; manufactured/labeled by Direct_Rx) offers oral-route delivery via 50 mg/1 / 40 mg/1 Tablet with structured clinical follow-up.
In oral-route clinical dosing (50 mg/1 / 40 mg/1 Tablet), Butal/Apap/Caff (manufactured/labeled by Direct_Rx; 72189-441) executes barbiturate molecular modulation paired with routine metabolic and excretory disposition.
Following administration (50 mg/1 / 40 mg/1 Tablet), Butal/Apap/Caff achieves Estimated 79%–91% oral systemic absorption for Butal/Apap/Caff bioavailability and peak plasma concentration (tmax) reached 1–3 hours post-dose for butal/apap/caff onset, governed by a Approximately 9–17 hours terminal plasma half-life for Butal/Apap/Caff terminal half-life through phase i/ii hepatic conjugation of butal/apap/caff coupled with glomerular and tubular renal excretion.
Before initiating Butal/Apap/Caff at 50 mg/1 / 40 mg/1 Tablet, clinical safety checklists rule out documented intolerance or hypersensitivity reaction involving butal/apap/caff (barbiturate); concurrent restricted medications flagged in section 4/7 of the butal/apap/caff dailymed monograph (rxn-72189441-3137). Logged tolerability patterns center on headache (7.7% of reports), nausea (7.6% of reports), dizziness (6.5% of reports).
Assess baseline hepatic panels and interacting prescriptions when starting Butal/Apap/Caff (barbiturate).
Botanical enzyme modulators may alter oral first-pass exposure of Butal/Apap/Caff; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Butal/Apap/Caff (barbiturate)
- Concurrent restricted medications flagged in Section 4/7 of the Butal/Apap/Caff DailyMed monograph (RXN-72189441-3137)
Logged Side-Effect Incidence (22 Reports)
Butal/Apap/Caff Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Butal/Apap/Caff)
Human clinical trial evidence for Butal/Apap/Caff is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Butal/Apap/Caff Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $3.1200/unit (~$93.60/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $330.41 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 22 Anonymous DotMD Community Micro-Logs | $134.86 / mo | View logs ↓ |
Butal/Apap/Caff Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Butal/Apap/Caff RxNorm Concept ID | RXN-72189441-3137 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3.1200 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $330.41 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $134.86 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 80.00% Worth It (22 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Butal/Apap/Caff Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Butal/Apap/Caff integrating DailyMed SPL (2026-07-01), CMS NADAC ($3.1200/unit), and 22 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Butal/Apap/Caff community threads and patient logs by age, biological sex, dosage, and treatment duration.